Accustem Sciences Inc. logo

Accustem Sciences Inc. (ACUT)

Market Closed
10 Aug, 20:00
OTC PINK OTC PINK
OTC PINK OTC PINK Primary
$
0. 15
-0.01
-6.4815%
$
2.6M Market Cap
- P/E Ratio
- Div Yield
155 Volume
0 Eps
$ 0.16
Previous Close
Add Transaction
Day Range
0.15 0.15
Year Range
0.15 2.33
Want to track ACUT and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Get Started For Free

Summary

ACUT closed yesterday lower at $0.15, a decrease of -6.4815% from Friday's close, completing a monthly decrease of -24.25% or -$0.05. Over the past 12 months, ACUT stock lost -81.377%.
ACUT is not paying dividends to its shareholders.
The last earnings report, released on Apr 21, 2026, exceeded the consensus estimates by 0%. On average, the company has fell short of earnings expectations by -0.0123%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on one exchange.

ACUT Chart

No Data

People also search for

DMFG
Decker Manufacturing Corporation
$ 57.01
0%
BLOZF
Cannabix Technologies Inc.
$ 0.39
+1.8421%
VICP
VicapSys Life Sciences Inc.
$ 1.45
0%
AURX
Nuo Therapeutics Inc.
$ 0.85
0%
QTZM
Quantumzyme Corp.
$ 0.8
+33.3333%

Accustem Sciences Inc. (ACUT) FAQ

What is the stock price today?

The current price is $0.15.

On which exchange is it traded?

Accustem Sciences Inc. is listed on OTC PINK.

What is its stock symbol?

The ticker symbol is ACUT.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 2.6M.

Has Accustem Sciences Inc. ever had a stock split?

No, there has never been a stock split.

Accustem Sciences Inc. Profile

Biotechnology Industry
Healthcare Sector
Wendy E. Blosser CEO
OTC PINK Exchange
00444A101 CUSIP
US Country
4 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

AccuStem Sciences, Inc. represents a pioneering force in the life sciences sector, concentrating its efforts on the development and commercialization of innovative products aimed at improving the treatment and management practices for a variety of cancers. With a primary focus on genomics-based personalized medicine, AccuStem Sciences targets the treatment protocols for breast and lung cancer patients, aiming to tailor medical approaches to individual patient's genetic backgrounds. Established in 2013, with its headquarters in New York, New York, the company embarks on harnessing groundbreaking technologies to advance cancer care.

Products and Services

  • StemPrintER

    StemPrintER stands as AccuStem Sciences’ forefront product candidate, embodying a cutting-edge 20-gene prognostic assay. This innovative tool is designed to predict the likelihood of distant recurrence in patients suffering from luminal breast cancer. Through the analysis of specific gene expressions, StemPrintER provides a personalized risk assessment, enabling physicians to make more informed decisions regarding the necessity and intensity of adjuvant therapy. This assay exemplifies the company's commitment to individualized cancer therapy, steering the treatment plans towards a more targeted and effective approach.

Contact Information

Address: 5 Penn Plaza
Phone: +1 212 514 6245
Download app banner
Blog Affiliate Program About Terms Privacy Help Contact Us
2026 © Marketlog. All Rights Reserved.
Play store app banner Play store app banner dark App store app banner App store app banner dark